Response to Comment on "Cardiovascular and Adverse Effects of Glucagon for the Management of Suspected Beta Blocker Toxicity: a Case Series"

J Med Toxicol. 2023 Apr;19(2):235-236. doi: 10.1007/s13181-023-00937-3. Epub 2023 Mar 3.

Authors

Lorrie A LeClair¹, Alicia M Senart²

Affiliations

¹ Department of Pharmacy, Inova Fairfax Medical Campus, 3300 Gallows Rd., Falls Church, VA, 22042, USA. lorrie.leclair@inova.org.
² Department of Pharmacy, Greater Baltimore Medical Center, 6701 N. Charles St., Towson, MD, 21204, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Adrenergic beta-Antagonists / therapeutic use
Cardiovascular System*
Drug-Related Side Effects and Adverse Reactions*
Glucagon / pharmacology
Glucagon / therapeutic use
Humans

Substances

Glucagon
Adrenergic beta-Antagonists